5570-78-5

Basic information

• Product Name: 1-isopropylpiperidin-4-ol
• Synonyms: 1-isopropylpiperidin-4-ol;1-(1-Methylethyl)piperidin-4-ol;1-isopropylpiperidin-4-ol(SALTDATA: FREE);4-Piperidinol,1-(1-Methylethyl)-;1-(1-Methylethyl)-4-piperidinol;N-isopropyl-4-hydroxypiperidine
• CAS NO: 5570-78-5
• Molecular Formula: C₈H₁₇NO
• Molecular Weight: 143.22668
• EINECS: 226-944-5
• Mol File: 5570-78-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 227℃
• Flash Point: 75℃
• Appearance: /
• Density: 0.976
• Vapor Pressure: 0.016mmHg at 25°C
• Refractive Index: 1.485
• Storage Temp.: 2-8°C
• PKA: 14.88±0.20(Predicted)
• CAS DataBase Reference: 1-isopropylpiperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-isopropylpiperidin-4-ol(5570-78-5)
• EPA Substance Registry System: 1-isopropylpiperidin-4-ol(5570-78-5)

Safety Data

• Hazardous Substances Data: 5570-78-5(Hazardous Substances Data)

Usage

General Description

1-isopropylpiperidin-4-ol is a chemical compound with the molecular formula C9H19NO. It is a piperidine derivative and is classified as a tertiary alcohol. 1-isopropylpiperidin-4-ol is used in the synthesis of pharmaceuticals and may have potential applications in medicinal chemistry. Its structure contains a piperidine ring with an isopropyl and an alcohol functional group, which gives it both hydrophobic and hydrophilic properties. The presence of the piperidine ring suggests that it may have biological activity, and further research may be conducted to explore its potential as a drug candidate.

InChI:InChI=1/C8H17NO/c1-7(2)9-5-3-8(10)4-6-9/h7-8,10H,3-6H2,1-2H3

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 75-26-3 isopropyl bromide 
• 67-64-1 acetone 
• 16217-23-5 3,3'-isopropylimino-di-propionic acid diethyl ester 
• 5355-68-0 1-Isopropyl-4-piperidone 

Downstream Products

• 1609660-68-5 C₂₁H₂₅F₂NO 
• 1260098-12-1 1-[4-(1-isopropyl-piperidin-4-yloxy)-phenyl]-2-morpholin-4-yl-ethanone 
• 912947-17-2 3-[(1-isopropylpiperidin-4-yl)oxy]benzonitrile 
• 397275-42-2 4-[(1-isopropyl-4-piperidinyl)oxy]benzonitrile 
• 1048954-89-7 C₂₅H₃₄N₂O₂ 

Relevant articles and documents

Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity

A series of chemical optimizations guided by in vitro affinity at a histamine H3 receptor (H3R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake-promoting effects with decreased rapid-eye-movement sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety studies in animals have been successfully completed without any concern for further development.

NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS

The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

NPY ANTAGONISTS, PREPARATION AND USES

The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.